Backbones versus core agents in initial ART regimens: One game, two players

Journal of Antimicrobial Chemotherapy

Volumn 71, Issue 4, 2016, Pages 856-861

  Llibre, Josep M ^a,b   Walmsley, Sharon ^c   Gatell, Josep M ^d  

^a HOSPITAL UNIVERSITARI GERMANS TRIAS I PUJOL   (Spain)

^b UNIVERSITAT AUTÒNOMA DE BARCELONA   (Spain)

^c UNIVERSITY HEALTH NETWORK   (Canada)

^d UNIVERSITY OF BARCELONA   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIRETROVIRUS AGENT; DOLUTEGRAVIR; EMTRICITABINE; HUMAN IMMUNODEFICIENCY VIRUS PROTEINASE INHIBITOR; INTEGRASE INHIBITOR; LAMIVUDINE; NONNUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITOR; VIRUS RNA; ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT;

ARTICLE; DISEASE MARKER; DRUG EFFICACY; DRUG SAFETY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MONOTHERAPY; NONHUMAN; TREATMENT OUTCOME; ADVERSE EFFECTS; COMBINATION DRUG THERAPY; DRUG INTERACTION; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HIV INFECTIONS; PATIENT SAFETY; PROCEDURES;

ANTI-HIV AGENTS; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; DRUG INTERACTIONS; DRUG THERAPY, COMBINATION; HIV INFECTIONS; HUMANS; PATIENT SAFETY;

EID: 84964388849     PISSN: 03057453     EISSN: 14602091     Source Type: Journal    
DOI: 10.1093/jac/dkv429     Document Type: Article

References (75)

1. Fischl MA, Richman DD, Grieco MH et al. The efficacy of azidothymidine (AZT) in the treatment of patients with AIDS and AIDS-related complex. A double-blind, placebo-controlled trial. N Engl J Med 1987; 317: 185-91.
2. Richman DD, Fischl MA, Grieco MH et al. The toxicity of azidothymidine (AZT) in the treatment of patients with AIDS and AIDS-related complex: a double blind, placebo-controlled trial. N Engl J Med 1987; 317: 192-7.
3. Volberding PA, Lagakos SW, Koch MA et al. Zidovudine in asymptomatic human immunodeficiency virus infection: a controlled trial in persons with fewer than 500 CD4-positive cells per cubic millimeter. The AIDS Clinical Trials Group of the National Institute of Allergy and Infectious Diseases. N Engl J Med 1990; 322: 941-9.
4. Cooper DA, Gatell JM, Kroon S et al. Zidovudine in persons with asymptomatic HIV infection and CD4+ cell counts greater than 400 per cubic millimeter. The European-Australian Collaborative Group. N Engl J Med 1993; 329: 297-303.
5. Connor EM, Sperling RS, Gelber R et al. Reduction of maternal-infant transmission of human immunodeficiency virus type 1 with zidovudine treatment. Pediatric AIDS Clinical Trials Group Protocol 076 Study Group. N Engl J Med 1994; 331: 1173-80.
6. Darbyshire JH, Aboulker JP. Delta: A randomised double-blind controlled trial comparing combinations of zidovudine plus didanosine or zalcitabine with zidovudine alone in HIV-infected individuals. Lancet 1996; 348: 283-91.
7. Hammer SM, Katzenstein DA, Hughes MD et al. A trial comparing nucleoside monotherapy with combination therapy in HIV-infected adults with CD4 cell counts from 200 to 500 per cubic millimeter. N Engl J Med 1996; 335: 1081-90.
8. Eron JJ, Benoit SL, Jemsek J et al. Treatment with lamivudine, zidovudine, or both in HIV-positive patients with 200 to 500 CD4+ cells per cubic millimeter. North American HIV Working Party. N Engl J Med 1995; 333: 1662-9.
9. Lathey JL, Hughes MD, Fiscus Sa et al. Variability and prognostic values of virologic and CD4 cell measures in human immunodeficiency virus type 1-infected patients with 200-500 CD4 cells/mm3 (ACTG 175). AIDS Clinical Trials Group Protocol 175 Team. J Infect Dis 1998; 177: 617-24.
10. Llibre JM, Arribas JR, Domingo P et al. Clinical implications of fixed-dose coformulations of antiretrovirals on the outcome of HIV-1 therapy. AIDS 2011; 25: 1683-90.
11. Gulick RM, Ribaudo HJ, Shikuma CM et al. Three-vs four-drug antiretroviral regimens for the initial treatment of HIV-1 infection: a randomized controlled trial. JAMA 2006; 296: 769-81.
12. Thompson M, Aberg J, Hoy J et al. Antiretroviral treatment of adult HIV infection. JAMA 2014; 308: 387-402.
13. Panel on Antiretroviral Guidelines for Adults and Adolescents. Guidelines for the Use of Antiretroviral Agents in HIV-1-Infected Adults and Adolescents. Department of Health and Human Services. http://aidsinfo.nih.gov/guidelines.
14. Expert Panel of GESIDA and the National AIDS Plan. Document on antiretroviral therapy in adults infected by the human immunodeficiency virus (updated January 2015). Enf Infecc Microbiol Clin 2015; 33: 544-56.
15. Montaner JS, Reiss P, Cooper D et al. A randomized, double-blind trial comparing combinations of nevirapine, didanosine, and zidovudine for HIV-infected patients: the INCAS Trial. Italy, The Netherlands, Canada and Australia Study. JAMA 1998; 279: 930-7.
16. Hammer SM, Squires K, Hughes MD et al. A controlled trial of two nucleoside analogues plus indinavir in persons with human immunodeficiency virus infection and CD4 cell counts of 200 per cubic millimeter or less. N Engl J Med 1997; 337: 725-33.
17. Staszewski S, Morales-Ramirez J, Tashima K et al. Efavirenz plus zidovudine and lamivudine, efavirenz plus indinavir, and indinavir plus zidovudine and lamivudine in the treatment of HIV-1 infection in adults. N Engl J Med 1999; 341: 1865-73.
18. Martinez E, Arnaiz JA, Podzamczer D et al. Substitution of nevirapine, efavirenz, or abacavir for protease inhibitors in patients with human immunodeficiency virus infection. N Engl J Med 2003; 349: 1036-46.
19. Martinez E, Arnaiz JA, Podzamczer D et al. Three-year follow-up of protease inhibitor-based regimen simplification in HIV-infected patients. AIDS 2007; 21: 365-9.
20. Mollan KR, Smurzynski M, Eron JJ et al. Association between efavirenz as initial therapy for HIV-1 infection and increased risk for suicidal ideation or attempted or completed suicide: an analysis of trial data. Ann Intern Med 2014; 161: 1-10.
21. Walmsley SL, Antela A, Clumeck N et al. Dolutegravir plus abacavirlamivudine for the treatment of HIV-1 infection. N Engl J Med 2013; 369: 1807-18.
22. Lennox JL, DeJesus E, Lazzarin A et al. Safety and efficacy of raltegravirbased versus efavirenz-based combination therapy in treatment-naive patients with HIV-1 infection: a multicentre, double-blind randomised controlled trial. Lancet 2009; 374: 796-806.
23. Lennox JL, Dejesus E, Berger DS et al. Raltegravir versus Efavirenz regimens in treatment-naive HIV-1-infected patients: 96-week efficacy, durability, subgroup, safety, and metabolic analyses. J Acquir Immune Defic Syndr 2010; 55: 39-48.
24. Rockstroh JK, Lennox JL, Dejesus E et al. Long-term treatment with raltegravir or efavirenz combined with tenofovir/emtricitabine for treatment-naive human immunodeficiency virus-1-infected patients: 156-week results from STARTMRK. Clin Infect Dis 2011; 53: 807-16.
25. DeJesus E, Rockstroh JK, Lennox JL et al. Efficacy of raltegravir versus efavirenz when combined with tenofovir/emtricitabine in treatment-naïve HIV-1-infected patients: Week-192 overall and subgroup analyses from STARTMRK. HIV Clin Trials 2012; 13: 228-32.
26. Cohen CJ, Andrade-Villanueva J, Clotet B et al. Rilpivirine versus efavirenz with two background nucleoside or nucleotide reverse transcriptase inhibitors in treatment-naive adults infected with HIV-1 (THRIVE): A phase 3, randomised, non-inferiority trial. Lancet 2011; 378: 229-37.
27. Molina JM, Cahn P, Grinsztejn B et al. Rilpivirine versus efavirenz with tenofovir and emtricitabine in treatment-naive adults infected with HIV-1 (ECHO): A phase 3 randomised double-blind active-controlled trial. Lancet 2011; 378: 238-46.
28. Cohen C, Wohl D, Arribas JR et al. Week 48 results from a randomized clinical trial of rilpivirine/emtricitabine/tenofovir disoproxil fumarate vs. efavirenz/emtricitabine/tenofovir disoproxil fumarate in treatment-naive HIV-1-infected adults. AIDS 2014; 28: 989-97.
29. Cohen CJ, Molina J-M, Cahn P et al. Efficacy and safety of rilpivirine (TMC278) versus efavirenz at 48 weeks in treatment-naive HIV-1-infected patients. J Acquir Immune Defic Syndr 2012; 60: 33-42.
30. Feng M, Wang D, Grobler JA et al. In vitro resistance selection with doravirine (MK-1439), a novel nonnucleoside reverse transcriptase inhibitor with distinct mutation development pathways. Antimicrob Agents Chemother 2015; 59: 590-8.
31. Collier AC, Coombs RW, Schoenfeld DA et al. Treatment of human immunodeficiency virus infection with saquinavir, zidovudine, and zalcitabine. N Engl J Med 1996; 334: 1011-8.
32. Markowitz M, Saag M, Powderly WG et al. A preliminary study of ritonavir, an inhibitor of HIV-1 protease, to treat HIV-1 infection. N Engl J Med 1995; 333: 1534-9.
33. Gulick R, Mellors J, Havlir D et al. Treatment with indinavir, zidovudine, and lamivudine in adults with human immunodeficiency virus infection and prior antiretroviral therapy. N Engl J Med 1997; 337: 734-9.
34. Llibre JM. First-line boosted protease inhibitor-based regimens in treatment-naive HIV-1-infected patients-making a good thing better. AIDS Rev 2009; 11: 215-22.
35. Markowitz M, Conant M, Hurley A et al. A preliminary evaluation of nelfinavir mesylate, an inhibitor of human immunodeficiency virus (HIV)-1 protease, to treat HIV infection. J Infect Dis 1998; 177: 1533-40.
36. Kempf DJ, Isaacson JD, King MS et al. Identification of genotypic changes in human immunodeficiency virus protease that correlate with reduced susceptibility to the protease inhibitor lopinavir among viral isolates from protease inhibitor-experienced patients. J Virol 2001; 75: 7462-9.
37. Kempf D, Marsh K, Kumar G et al. Pharmacokinetic enhancement of inhibitors of the human immunodeficiency virus protease by coadministration with ritonavir. Antimicrob Agents Chemother 1997; 41: 654-60.
38. Walmsley S, Bernstein B, King M et al. Lopinavir-ritonavir versus nelfinavir for the initial treatment of HIV infection. N Engl J Med 2002; 346: 2039-46.
39. Walmsley S, Avihingsanon A, Slim J et al. Gemini: a noninferiority study of saquinavir/ritonavir versus lopinavir/ritonavir as initial HIV-1 therapy in adults. J Acquir Immune Defic Syndr 2009; 50: 367-74.
40. Eron J, Yeni P, Gathe J et al. The KLEAN study of fosamprenavir-ritonavir versus lopinavir-ritonavir, each in combination with abacavir-lamivudine, for initial treatment of HIV infection over 48 weeks: a randomised noninferiority trial. Lancet 2006; 368: 476-82.
41. Carr A, Samaras K, Thorisdottir A et al. Diagnosis, prediction, and natural course of HIV-1 protease-inhibitor-associated lipodystrophy, hyperlipidaemia, and diabetes mellitus: a cohort study. Lancet 1999; 353: 2093-9.
42. Molina JM, Andrade-Villanueva J, Echevarria J et al. Once-daily atazanavir/ritonavir versus twice-daily lopinavir/ritonavir, each in combination with tenofovir and emtricitabine, for management of antiretroviral-naive HIV-1-infected patients: 48 week efficacy and safety results of the CASTLE study. Lancet 2008; 372: 646-55.
43. Malan DR, Krantz E, David N et al. Efficacy and safety of atazanavir, with or without ritonavir, as part of once-daily highly active antiretroviral therapy regimens in antiretroviral-naive patients. J Acquir Immune Defic Syndr 2008; 47: 161-7.
44. Ortiz R, Dejesus E, Khanlou H et al. Efficacy and safety of once-daily darunavir/ritonavir versus lopinavir/ritonavir in treatment-naive HIV-1-infected patients at week 48. AIDS 2008; 22: 1389-97.
45. Llibre JM, Imaz A, Clotet B. From TMC114 to darunavir: Five years of data on efficacy. AIDS Rev 2013; 15: 112-21.
46. Llibre JM, Schapiro JM, Clotet B. Clinical implications of genotypic resistance to the newer antiretroviral drugs in HIV-1-infected patients with virological failure. Clin Infect Dis 2010; 50: 872-81.
47. Mills AM, Nelson M, Jayaweera D et al. Once-daily darunavir/ritonavir vs. lopinavir/ritonavir in treatment-naive, HIV-1-infected patients: 96-week analysis. AIDS 2009; 23: 1679-88.
48. Lennox JL, Landovitz RJ, Ribaudo HJ et al. Efficacy and tolerability of 3. nonnucleoside reverse transcriptase inhibitor-sparing antiretroviral regimens for treatment-naive volunteers infected with HIV-1. A randomized, controlled equivalence trial. Ann Intern Med 2014; 161: 461-71.
49. EACS European AIDS Clinical Society. Guidelines. Version 8.0, October 2015. http://www.eacsociety.org/.
50. Cooper DA, Heera J, Goodrich J et al. Maraviroc versus efavirenz, both in combination with zidovudine-lamivudine, for the treatment of antiretroviral-naive subjects with CCR5-tropic HIV-1 infection. J Infect Dis 2010; 201: 803-13.
51. Steigbigel RT, Cooper DA, Kumar PM et al. Raltegravir with optimized background therapy for resistant HIV-1 infection. N Engl J Med 2008; 359: 339-54.
52. Cooper DA, Steigbigel RT, Gatell JM et al. Subgroup and resistance analyses of raltegravir for resistant HIV-1 infection. N Engl J Med 2008; 359: 355-65.
53. DeJesus E, Rockstroh JK, Henry K et al. Co-formulated elvitegravir, cobicistat, emtricitabine, and tenofovir disoproxil fumarate versus ritonavir-boosted atazanavir plus co-formulated emtricitabine and tenofovir disoproxil fumarate for initial treatment of HIV-1 infection: a randomised, double-blind, phase 3, non-inferiority trial. Lancet 2012; 379: 2429-38.
54. Sax PE, DeJesus E, Mills A et al. Co-formulated elvitegravir, cobicistat, emtricitabine, and tenofovir versus co-formulated efavirenz, emtricitabine, and tenofovir for initial treatment of HIV-1 infection: a randomised, double-blind, phase 3 trial, analysis of results after 48 weeks. Lancet 2012; 379: 2439-48.
55. Squires K, Kityo C, Hodder S et al. Elvitegravir (EVG)/cobicistat (COBI)/emtricitabine (FTC)/tenofovir disoproxil fumarate (TDF) is superior to ritonavir (RTV) boosted atazanavir (ATV) plus FTC/TDF in treatment naivewomen with HIV-1 infection (WAVES study). In: Abstracts of the Eighth IAS Conference on HIV Pathogenesis, Treatment and Prevention, Vancouver, Canada, 2015. Abstract MOLBPE08.
56. Raffi F, Rachlis A, Stellbrink H et al. Once-daily dolutegravir versus raltegravir in antiretroviral-naive adults with HIV-1 infection: 48 week results from the randomised, double-blind, non-inferiority SPRING-2 study. Lancet 2013; 381: 735-43.
57. Clotet B, Feinberg J, Van Lunzen J et al. Once-daily dolutegravir versus darunavir plus ritonavir in antiretroviral-naive adults with HIV-1 infection (FLAMINGO): 48 week results from the randomised open-label phase 3b study. Lancet 2014; 383: 2222-31.
58. Oliveira M, Mesplède T, Quashie PK et al. Resistance mutations against dolutegravir in HIV integrase impair the emergence of resistance against reverse transcriptase inhibitors. AIDS 2014; 28: 813-9.
59. Quashie PK, Mesplede T, Han Y-S et al. Characterization of the R263K mutation in HIV-1 integrase that confers low-level resistance to the second-generation integrase strand transfer inhibitor dolutegravir. J Virol 2012; 86: 2696-705.
60. Llibre JM, Pulido F, García F et al. Genetic barrier to resistance for dolutegravir. AIDS Rev 2015; 17: 56-64.
61. Smith KY, Patel P, Fine D et al. Randomized, double-blind, placebomatched, multicenter trial of abacavir/lamivudine or tenofovir/emtricitabine with lopinavir/ritonavir for initial HIV treatment. AIDS 2009; 23: 1547-56.
62. Sax PE, Tierney C, Collier A et al. Abacavir-lamivudine versus tenofovir-emtricitabine for initial HIV-1 therapy. N Engl J Med 2009; 361: 2230-40.
63. Daar ES, Tierney C, Fischl MA et al. Atazanavir plus ritonavir or efavirenz as part of a 3-drug regimen for initial treatment of HIV-1: A randomized trial. Ann Intern Med 2011; 154: 445-56.
64. Cahn P, Andrade-Villanueva J, Arribas JR et al. Dual therapy with lopinavir and ritonavir plus lamivudine versus triple therapy with lopinavir and ritonavir plus two nucleoside reverse transcriptase inhibitors in antiretroviral-therapy-naive adults with HIV-1 infection: 48 week results of the randomized, open label, non-inferiority GARDEL trial. Lancet Infect Dis 2014; 14: 572-80.
65. Cahn P, on behalf of the GARDEL Study Group. Durability of dual therapy (DT) with lopinavir/ritonavir (LPV/r) and lamivudine (3TC) in comparison to standard triple drug therapy (TT): 96-week results of the GARDEL study. In: Abstracts of the Fifteenth European AIDS Conference, Barcelona, Spain, 2015. Abstract PS10/4.
66. Arribas JR, Girard P-M, Landman R et al. Dual treatment with lopinavir-ritonavir plus lamivudine versus triple treatment with lopinavir-ritonavir plus lamivudine or emtricitabine and a second nucleos(t)ide reverse transcriptase inhibitor for maintenance of HIV-1 viral suppression (OLE): a randomised, open-label, non-inferiority trial. Lancet Infect Dis 2015; 15: 785-92.
67. Perez-Molina JA, Rubio R, Rivero A et al. Dual treatment with atazanavir-ritonavir plus lamivudine versus triple treatment with atazanavir-ritonavir plus two nucleos(t)ides in virologically stable patients with HIV-1 (SALT): 48 week results from a randomised, open-label, noninferiority trial. Lancet Infect Dis 2015; 15: 775-84.
68. Delfraissy J-F, Flandre P, Delaugerre C et al. Lopinavir/ritonavir monotherapy or plus zidovudine and lamivudine in antiretroviral-naive HIV-infected patients. AIDS 2008; 22: 385-93.
69. Raffi F, Babiker AG, Richert L et al. Ritonavir-boosted darunavir combined with raltegravir or tenofovir-emtricitabine in antiretroviral-naive adults infected with HIV-1: 96 week results from the NEAT001/ANRS143 randomised non-inferiority trial. Lancet 2014; 6736: 1-10.
70. Reynes J, Lawal A, Pulido F et al. Examination of noninferiority, safety, and tolerability of lopinavir/ritonavir and raltegravir compared with lopinavir/ritonavir and tenofovir/emtricitabine in antiretroviral-naïve subjects: The PROGRESS Study, 48-week results. HIV Clin Trials 2011; 12: 255-67.
71. Taiwo BO, Chan ES, Fichtenbaum CJ et al. Less bone loss with maraviroc-compared to tenofovir-containing antiretroviral therapy in the ACTG A5303 Study. Clin Infect Dis 2015; 61: 1179-88.
72. Rousseau FS, Wakeford C, Mommeja-Marin H et al. Prospective randomized trial of emtricitabine versus lamivudine short-term monotherapy in human immunodeficiency virus-infected patients. J Infect Dis 2003; 188: 1652-8.
73. Figueroa MI, Sued O, Patterson P et al. Dolutegravir-lamivudine as initial therapy in HIV-infected, ARV naive patients: first results of the PADDLE trial. In: Abstracts of the Fifteenth European AIDS Conference, Barcelona, Spain, 2015. Abstract LBPS4/1.
74. Sax PE, Wohl D, Yin MT et al. Tenofovir alafenamide versus tenofovir disoproxil fumarate, coformulated with elvitegravir, cobicistat, and emtricitabine, for initial treatment of HIV-1 infection: two randomised, double-blind, phase 3, non-inferiority trials. Lancet 2015; 385: 2606-15.
75. Mills AM, Andrade-Villanueva J, Di Perri G et al. Switching from a tenofovir disoproxil fumarate (TDF)-based regimen to a tenofovir alafenamide (TAF)-based regimen: data in virologically suppressed adults through 48 weeks of treatment. In: Abstracts of the Eighth IAS Conference on HIV Pathogenesis, Treatment and Prevention, Vancouver, Canada, 2015. Abstract TUAB0102.